Related Experiment Videos
Effects of enalapril on tissue factor in patients with uncomplicated acute myocardial infarction
Insights
Enalapril therapy significantly reduced elevated plasma tissue factor antigen levels in patients recovering from myocardial infarction. This finding may explain the reduced coronary thrombosis risk associated with angiotensin-converting enzyme inhibitors.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Acute myocardial infarction (MI) is a leading cause of cardiovascular mortality.
- Tissue factor (TF) plays a critical role in the coagulation cascade and thrombosis.
- Elevated TF levels have been observed in patients post-MI.
Purpose of the Study:
- To investigate plasma tissue factor antigen levels in patients after acute myocardial infarction.
- To evaluate the effect of enalapril therapy on these levels.
- To explore the potential link between TF levels, enalapril, and coronary thrombosis risk.
Main Methods:
- Randomized, double-blind, placebo-controlled study design.
- Participants initiated enalapril therapy 4 weeks after uncomplicated acute MI.
- Plasma tissue factor antigen levels were measured at baseline and during therapy.
Main Results:
- Baseline plasma tissue factor antigen levels were significantly higher in MI patients compared to controls.
- Enalapril therapy significantly reduced the elevated plasma tissue factor antigen levels.
- The reduction in TF levels correlated with the known benefits of ACE inhibitors in reducing coronary thrombosis.
Conclusions:
- Plasma tissue factor antigen is elevated after acute myocardial infarction.
- Enalapril therapy effectively reduces these elevated levels.
- This TF reduction may contribute to the cardioprotective effects of angiotensin-converting enzyme inhibitors in MI patients.
Abstract:
In a randomized, double-blind, placebo-controlled study beginning 4 weeks after uncomplicated acute myocardial infarction, it was established that the baseline plasma tissue factor antigen level was significantly higher in patients with myocardial infarction than in control subjects, and enalapril therapy significantly reduced the elevated plasma tissue factor antigen level. This may be associated with the reduction in the risk of coronary thrombosis seen with the use of angiotensin-converting enzyme inhibitors.